<DOC>
	<DOCNO>NCT02080364</DOCNO>
	<brief_summary>This study evaluate efficacy safety azeliragon patient mild Alzheimer 's disease . Patients receive either azeliragon placebo patient 's participation lasting approximately 18 month .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Azeliragon ( TTP488 ) Patients With Mild Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Diagnosis probable Alzheimer Disease ( AD ) document evidence progression disease Mini Mental State Examination ( MMSE ) score 2126 , inclusive Clinical Dementia Rating global score 0.5 1 RosenModified Hachinski Ischemia Score less equal 4 Brain magnetic resonance imaging ( MRI ) consistent diagnosis probable AD Concurrent use cholinesterase inhibitor memantine stable dose least 3 month prior randomization Caregiver willing participate able attend clinic visit patient Ability ingest oral medication Significant neurological psychiatric disease Alzheimer 's disease Participants evidence history severe drug allergy ( result dyspnea severe rash ) . Any contraindication MRI ( e.g. , clinically significant claustrophobia , nonremovable ferromagnetic implant ) . Patients contraindication MRI may undergo compute tomography ( CT ) approval sponsor . Any contraindication FDGPET study ( e.g . allergy component FDG dose ) cohort undergo PET scan . Previous exposure investigational noninvestigational therapy Alzheimer 's disease within 6 month screen History cancer within last 5 year except adequately treated cervical carcinoma insitu , cutaneous basal cell squamous cell cancer , nonprogressive prostate cancer require treatment Women childbearing potential Uncontrolled blood pressure and/or blood pressure 160/100 Prescription medical food intend dietary management metabolic process associate Alzheimer 's disease . Diagnosis history cerebrovascular stroke , severe carotid stenosis , cerebral hemorrhage , intracranial tumor , subarachnoid hemorrhage . Patients unstable , uncontrolled diabetes ( HbA1c &gt; 7.7 % ) require insulin .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>RAGE</keyword>
	<keyword>ADAS-cog</keyword>
	<keyword>CDR-sb</keyword>
</DOC>